无聊的语风
Lv0
0 积分
2024-09-10 加入
-
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
2小时前
已完结
-
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions
8天前
已完结
-
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
1个月前
已完结
-
Ivonescimab: First Approval
1个月前
已完结
-
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
1个月前
已完结
-
单剂量二氯化镭-223(BAY 88-8223)在去势抵抗性前列腺癌骨转移日本患者中的药代动力学研究
2个月前
已完结
-
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
2个月前
已完结
-
Alpha-emitter Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors
2个月前
已完结
-
Changes in categorization or nomenclature within neuroendocrine tumors
2个月前
已关闭
-
161Tb标记放射性药物的研究进展
2个月前
已完结